Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 90

Sort by

Sort Order Select

Journal Articles

Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma

Pier Luigi Zinzani, Jiri Mayer, Christopher Flowers, Fontanet Bijou, Ana C. De Oliveira, Yuqin Song, Qing-Yuan Zhang, Marco Brociner, Krimo Bouabdallah, Peter S. Ganly, Huilai Zhang, Sam Yuen, Marek Trneny, Rebecca Auer, Sha Huang, Jiayi Shen, Jamie Hirata, Judith Trotman

Blood (2025) 146 (Supplement 1): 227.

https://doi.org/10.1182/blood-2025-227

Published: 2025

Journal Articles

Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial

Blood (2025) 146 (Supplement 1): 5361.

https://doi.org/10.1182/blood-2025-5361

Published: 2025

Journal Articles

An immunometabolic companion biomarker to enhance FDG-PET interpretation and guide frontline therapy in follicular lymphoma

Blood (2025) 146 (Supplement 1): 5338.

https://doi.org/10.1182/blood-2025-5338

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

Romain Guieze, Annamaria Frustaci, Chan Cheah, John Seymour, Dok Hyun Yoon, Irina Mocanu, Eric Mou, Pier Luigi Zinzani, Amitkumar Mehta, Constantine Tam, Judith Trotman, Yanan Zhang, Linlin Xu, Kunthel By, Amber Lussier, Shannon Fabre, Daniel Persky, Ranjana Advani

Blood (2025) 146 (Supplement 1): 3584.

https://doi.org/10.1182/blood-2025-3584

Published: 2025

Journal Articles

WM-voice: An international discrete choice experiment on treatment preferences in 1,455 patients with Waldenström macroglobulinemia

Anne-Marie Becking, Pythia Nieuwkerk, Michelle Postek, Karima Amaador, Sophie Bernelot Moens, Linda Bronsgeest, Shirley D'Sa, Pierre Faubert, Carl Harrington, Paul Kitchen, David Macdonald, Monique Minnema, Alison McKinney, Lia Palomba, Ibrahim Tohidi-Esfahani, Judith Trotman, Andrew Warden, Marie José Kersten, Josephine Vos

Blood (2025) 146 (Supplement 1): 519.

https://doi.org/10.1182/blood-2025-519

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study

Blood (2025) 146 (Supplement 1): 85.

https://doi.org/10.1182/blood-2025-85

Published: 2025

Journal Articles

Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated study

Ross Salvaris, Colm Keane, Judith Trotman, Antony Sutherland, Mark Waltham, David Simpson, Gareth P. Gregory, Stephen Opat

Blood (2025) 146 (Supplement 1): 1926.

https://doi.org/10.1182/blood-2025-1926

Published: 2025

Journal Articles

EZH2 and CREBBP mutation status identify a subset of patients who benefit from bendamustine- over CHOP/CVP-based immunochemotherapies in follicular lymphoma: Findings from the GALLIUM trial and validation in a large international cohort

Blood (2025) 146 (Supplement 1): 52.

https://doi.org/10.1182/blood-2025-52

Published: 2025

Journal Articles

Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical

Ryan Low, Andrew Warden, Michelle Postek, Peter Denardis, Charalampia Kyriakou, Adam J. Olszewski, Marie José Kersten, Josephine M.I. Vos, Sheeba K. Thomas, Shirley D'Sa, Newton Guerin, Carl Harrington, Judith Trotman, Ibrahim Tohidi-Esfahani

Blood (2024) 144 (Supplement 1): 1654.

https://doi.org/10.1182/blood-2024-202820

Published: 2024

Journal Articles

Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Blood (2024) 144 (Supplement 1): 3019.

https://doi.org/10.1182/blood-2024-204328

Published: 2024

Journal Articles

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3007.

https://doi.org/10.1182/blood-2024-202088

Published: 2024

Journal Articles

Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)

Judith Trotman, Katherine Rankin, Ibrahim Tohidi-Esfahani, Alessandra Tedeschi, Constantine S. Tam, Christian Buske, Roger G Owen, Veronique LeBlond, Meletios A. Dimopoulos, Peter Smallwood, Heather Allewelt, Wai Y Chan, Radha Prathikanti, Jingjing Schneider, Remus Vezan, Stephen S. Opat

Blood (2024) 144 (Supplement 1): 4412.

https://doi.org/10.1182/blood-2024-200334

Published: 2024

Journal Articles

Comparative Efficacy of Zanubrutinib Plus Obinutuzumab Versus Last Prior Treatment in Relapsed/Refractory Follicular Lymphoma: Growth Modulation Index Analysis from ROSEWOOD Study

Judith Trotman, Pier Luigi Zinzani, Krimo Bouabdallah, Shanmei Liao, Adam Greenbaum, Laura Dima, Laurent Dumartin

Blood (2024) 144 (Supplement 1): 3029.

https://doi.org/10.1182/blood-2024-198500

Published: 2024

Journal Articles

Iopofosine I 131 in Previously Treated Patients with Waldenström Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™)

Blood (2024) 144 (Supplement 1): 861.

https://doi.org/10.1182/blood-2024-200277

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study

John F. Seymour, Constantine S. Tam, Chan Y. Cheah, Ricardo D. Parrondo, John N. Allan, Judith Trotman, Ranjana H. Advani, Herbert A. Eradat, Pier Luigi Zinzani, Masa Lasica, Steven P. Treon, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, Anna Maria Frustaci

Blood (2024) 144 (Supplement 1): 860.

https://doi.org/10.1182/blood-2024-199212

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

Meghan C. Thompson, Ricardo D. Parrondo, Anna Maria Frustaci, John N. Allan, Paolo Ghia, Irina Mocanu, Constantine S. Tam, Judith Trotman, Inhye E. Ahn, Stephan Stilgenbauer, Lydia Scarfo, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, John F. Seymour

Blood (2024) 144 (Supplement 1): 885.

https://doi.org/10.1182/blood-2024-199116

Published: 2024

Journal Articles

Bleomycin Affects Lung Function for at Least 5 Years after Treatment for Hodgkin Lymphoma - Data from the International, Randomised Phase 3 Rathl Trial

Elizabeth H Phillips, Amy A Kirkwood, Christina Hague, Jorgen Vestbo, Massimo Federico, Francesco D'Amore, Alexander Fossa, Judith Trotman, Leanne Berkahn, Daniel L. Molin, Stefano Luminari, Sally F Barrington, Peter Johnson, John Radford

Blood (2023) 142 (Supplement 1): 612.

https://doi.org/10.1182/blood-2023-185818

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib+ Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial

Judith Trotman, Pier Luigi Zinzani, Yuqin Song, Richard Delarue, Gisoo Barnes, Pil Kim, Elena Ivanova, Boxiong Tang, Jiří Mayer, Ana C. De Oliveira, Sarit Assouline, Christopher R. Flowers

Blood (2023) 142 (Supplement 1): 1674.

https://doi.org/10.1182/blood-2023-181195

Published: 2023

Journal Articles

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Blood (2023) 142 (Supplement 1): 1295.

https://doi.org/10.1182/blood-2023-181541

Published: 2023

Journal Articles

The Nature of High-Risk Defining Events in Follicular Lymphoma Determines Overall Survival

Blood (2023) 142 (Supplement 1): 1671.

https://doi.org/10.1182/blood-2023-185879

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma

Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial

An immunometabolic companion biomarker to enhance FDG-PET interpretation and guide frontline therapy in follicular lymphoma

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

WM-voice: An international discrete choice experiment on treatment preferences in 1,455 patients with Waldenström macroglobulinemia

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study

Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated study

EZH2 and CREBBP mutation status identify a subset of patients who benefit from bendamustine- over CHOP/CVP-based immunochemotherapies in follicular lymphoma: Findings from the GALLIUM trial and validation in a large international cohort

Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical

Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)

Comparative Efficacy of Zanubrutinib Plus Obinutuzumab Versus Last Prior Treatment in Relapsed/Refractory Follicular Lymphoma: Growth Modulation Index Analysis from ROSEWOOD Study

Iopofosine I 131 in Previously Treated Patients with Waldenström Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™)

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

Bleomycin Affects Lung Function for at Least 5 Years after Treatment for Hodgkin Lymphoma - Data from the International, Randomised Phase 3 Rathl Trial

Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib+ Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

The Nature of High-Risk Defining Events in Follicular Lymphoma Determines Overall Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only